Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00042783
Other study ID # CDR0000069468
Secondary ID SWOG-S0116
Status Completed
Phase Phase 2
First received August 5, 2002
Last updated June 21, 2013
Start date September 2002
Est. completion date March 2006

Study information

Verified date April 2004
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Vaccine therapy may be effective in treating stage IV melanoma.

PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma.


Description:

OBJECTIVES:

- Determine the feasibility of treating patients with stage IV melanoma with D1/3-MAGE-3-His fusion protein with SB-AS02B adjuvant.

- Determine the clinically confirmed response rates (partial and complete responses) of patients treated with this regimen.

- Determine the 6-month progression-free survival rate of patients treated with this regimen.

- Determine the qualitative and quantitative toxic effects of this regimen in these patients.

- Determine immune responses in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive D1/3-MAGE-3-His fusion protein emulsified in SB-AS02B adjuvant intramuscularly once every 3 weeks for a total of 12 weeks (4 injections). In the absence of disease progression or unacceptable toxicity, patients receive a second 12-week course beginning at week 16.

Patients are followed every 3 months for 1 year and then every 6 months for 2 years.

PROJECTED ACCRUAL: A total of 25-45 patients will be accrued for this study within 5-9 months.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date March 2006
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed stage IV melanoma that is considered incurable by surgery, radiotherapy, or limb perfusion

- M1a or M1b disease

- Measurable disease outside prior field of limb perfusion

- Metastatic mucosal melanoma allowed

- MAGE-3 positive by reverse transcription polymerase chain reaction

- No uveal or choroidal primary melanoma

- No prior or concurrent brain metastases by CT scan or MRI of the brain

PATIENT CHARACTERISTICS:

Age

- Not specified

Performance status

- Zubrod 0-1

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Hepatitis B surface antigen negative

- Hepatitis C negative

- No liver cirrhosis

- No unstable liver disease

- No coagulation disorders

Renal

- Not specified

Cardiovascular

- No major cardiovascular illness

- No myocardial infarction within the past 6 months

Pulmonary

- No major pulmonary illness

Other

- Not pregnant or nursing

- Fertile patients must use effective contraception

- HIV negative

- No AIDS or HIV-1-associated complex

- No chronic alcohol abuse or drug addiction

- No systemic infections

- No prior active autoimmune disease

- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer from which the patient is currently disease-free

PRIOR CONCURRENT THERAPY:

Biologic therapy

- At least 4 weeks since prior adjuvant biologic therapy

- No prior biologic therapy for stage IV melanoma

- No prior MAGE-3 peptide or protein vaccine preparation

Chemotherapy

- At least 4 weeks since prior adjuvant chemotherapy

- No prior chemotherapy for stage IV melanoma

Endocrine therapy

- Not specified

Radiotherapy

- At least 4 weeks since prior adjuvant radiotherapy

Surgery

- At least 4 weeks since prior surgery

Other

- See Disease Characteristics

- At least 3 weeks since prior limb perfusion and recovered

- At least 4 weeks since other prior adjuvant therapy

- No other prior therapy for stage IV melanoma

Study Design

Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
D1/3-MAGE-3-His fusion protein

SB-AS02B adjuvant


Locations

Country Name City State
United States Veterans Affairs Medical Center - Biloxi Biloxi Mississippi
United States Barbara Ann Karmanos Cancer Institute Detroit Michigan
United States Jonsson Comprehensive Cancer Center, UCLA Los Angeles California
United States USC/Norris Comprehensive Cancer Center and Hospital Los Angeles California
United States CCOP - Columbia River Oncology Program Portland Oregon
United States University of Washington School of Medicine Seattle Washington
United States Arizona Cancer Center at University of Arizona Health Sciences Center Tucson Arizona

Sponsors (2)

Lead Sponsor Collaborator
Southwest Oncology Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT04062032 - Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma Phase 2
Completed NCT03620019 - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Phase 2
Active, not recruiting NCT03291002 - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC Phase 1
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Completed NCT00962845 - Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery Early Phase 1
Completed NCT00324623 - Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma Phase 1
Completed NCT00096382 - Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00104845 - Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Phase 1
Completed NCT00089193 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Phase 2
Completed NCT00072085 - Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00072124 - Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma Phase 3
Active, not recruiting NCT00039234 - Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Phase 3
Completed NCT00049010 - Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma N/A
Completed NCT00006385 - Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00005610 - Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung Phase 2
Completed NCT00006022 - Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer Phase 1
Completed NCT00020358 - Vaccine Therapy in Treating Patients With Melanoma Phase 2
Recruiting NCT03767348 - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Phase 2
Withdrawn NCT00006126 - Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery Phase 1
Active, not recruiting NCT00002845 - Interleukin-2 in Treating Patients With Metastatic Melanoma Phase 2